XLV, the Health Care Select Sector SPDR ETF, enters the final days of June with a quietly contradictory setup: short interest is at its highest level in a month, yet options traders are pulling back their defensive hedges at the fastest rate in weeks.
The positioning story has shifted meaningfully since last week's note. Short interest climbed to 4.0% of the float — roughly 10.4 million shares — a 9.2% rise on the week and the highest reading since late May. That continues the rebuilding trend flagged on June 17, when shorts had recovered to 3.71% after the prior unwind. The June 8 peak of around 10.3 million shares has now been eclipsed. Borrow costs have moved with it: the cost to borrow has risen nearly 40% over the past month, touching 0.59% on June 23, up from 0.28% in late May. That said, the rate remains firmly in "low" territory — this is gradual pressure, not a squeeze. Availability has also tightened sharply over the same stretch, dropping from over 2,000% in late May to 213% now, though that still represents ample supply relative to current short positioning.
Options are telling a different story, and the divergence is worth naming. Put/call positioning has turned notably less defensive than usual, with the PCR running at 1.19 — almost 1.8 standard deviations below its 20-day average of 1.29. That gap is the sharpest reversal in the recent history of this data. Through most of May and the first half of June, the PCR held consistently above 1.27; the drop to current levels over the past two sessions suggests options traders are unwinding downside protection even as short sellers are rebuilding. The 52-week range for the PCR runs from 0.47 to 2.67, so the current level sits in the lower-middle of that band — not extreme, but the direction of travel is clearly toward less caution.
The ORTEX short score has tracked the same arc. It has risen steadily from 36.6 on June 10 to 46.7 now — a near doubling in two weeks — though it remains in neutral territory rather than signalling any extreme short pressure. That gradual climb reflects the rebuilding short interest and the tightening borrow rather than anything more urgent. Price action has been range-bound: XLV closed at $152.18 on June 23, roughly flat on the week after a 1.4% bounce on the day. The one-month performance is still a positive 1.5%, and the ETF has not broken the pattern of quiet outperformance that made it a defensive anchor earlier in the quarter.
On the institutional side, the Q1 ownership data — the most recent available — showed Managed Account Advisors LLC adding over 2.8 million shares to hold 8.6% of the fund. JPMorgan trimmed modestly while Goldman and Goldman Asset Management both added. The holder count of 434 is broadly stable, with no single large-scale exit visible. A $0.66 quarterly dividend was paid on June 22, up from $0.59 in March and above the $0.50 level seen in the same period of 2022, which offers a floor of income-driven demand.
What to watch is whether the divergence between rebuilding short interest and retreating options hedges narrows — specifically whether the PCR drifts back toward its recent average as healthcare policy and macro headlines shift the defensive calculus into July.
See the live data behind this article on ORTEX.
Open XLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
